Cantor Fitzgerald Predicts MDGL FY2025 Earnings

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Madrigal Pharmaceuticals in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst P. Agrawal expects that the biopharmaceutical company will earn ($9.20) per share for the year. Cantor Fitzgerald currently has a “Neutral” rating on the stock. The consensus estimate for Madrigal Pharmaceuticals’ current full-year earnings is ($23.55) per share.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last posted its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($4.92) EPS for the quarter, beating the consensus estimate of ($6.94) by $2.02. The firm had revenue of $62.18 million during the quarter, compared to analysts’ expectations of $34.60 million. During the same quarter last year, the business posted ($5.34) EPS.

Several other brokerages have also issued reports on MDGL. HC Wainwright raised their target price on Madrigal Pharmaceuticals from $390.00 to $400.00 and gave the company a “buy” rating in a research report on Tuesday, January 14th. StockNews.com raised shares of Madrigal Pharmaceuticals to a “sell” rating in a research report on Saturday, October 12th. JMP Securities reissued a “market outperform” rating and set a $427.00 target price on shares of Madrigal Pharmaceuticals in a research report on Friday, January 10th. B. Riley lifted their price target on shares of Madrigal Pharmaceuticals from $194.00 to $236.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Finally, Oppenheimer reduced their price objective on Madrigal Pharmaceuticals from $375.00 to $350.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat, Madrigal Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $351.67.

Madrigal Pharmaceuticals Price Performance

MDGL stock opened at $307.08 on Wednesday. The business has a 50 day moving average of $313.27 and a 200-day moving average of $272.85. Madrigal Pharmaceuticals has a 12-month low of $168.25 and a 12-month high of $368.29. The company has a quick ratio of 5.93, a current ratio of 5.98 and a debt-to-equity ratio of 0.15.

Insider Buying and Selling

In other Madrigal Pharmaceuticals news, General Counsel Shannon T. Kelley sold 277 shares of the firm’s stock in a transaction on Friday, January 17th. The shares were sold at an average price of $273.41, for a total value of $75,734.57. Following the completion of the transaction, the general counsel now directly owns 7,705 shares of the company’s stock, valued at $2,106,624.05. This trade represents a 3.47 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Robert E. Waltermire sold 442 shares of the business’s stock in a transaction on Friday, January 17th. The shares were sold at an average price of $273.41, for a total transaction of $120,847.22. Following the transaction, the vice president now owns 5,058 shares of the company’s stock, valued at $1,382,907.78. This trade represents a 8.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 14,408 shares of company stock valued at $4,489,207. Corporate insiders own 22.80% of the company’s stock.

Institutional Trading of Madrigal Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of MDGL. Erste Asset Management GmbH purchased a new position in shares of Madrigal Pharmaceuticals during the third quarter worth about $49,749,000. Paulson & CO. Inc. grew its stake in Madrigal Pharmaceuticals by 10.4% in the 3rd quarter. Paulson & CO. Inc. now owns 2,042,000 shares of the biopharmaceutical company’s stock worth $433,353,000 after buying an additional 192,000 shares in the last quarter. Braidwell LP bought a new position in shares of Madrigal Pharmaceuticals in the 3rd quarter worth $39,010,000. State Street Corp raised its position in shares of Madrigal Pharmaceuticals by 19.2% during the 3rd quarter. State Street Corp now owns 887,752 shares of the biopharmaceutical company’s stock valued at $188,399,000 after buying an additional 143,038 shares in the last quarter. Finally, Point72 Asset Management L.P. lifted its holdings in shares of Madrigal Pharmaceuticals by 172.6% during the 2nd quarter. Point72 Asset Management L.P. now owns 40,958 shares of the biopharmaceutical company’s stock worth $11,475,000 after acquiring an additional 97,387 shares during the last quarter. Hedge funds and other institutional investors own 98.50% of the company’s stock.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.